Passage Bio
Passage Bio Logo
About Passage Bio
Passage Bio Inc is a genetic medicines company focused on developing AAV-delivered gene therapies for rare, monogenic central nervous system diseases. Its pipeline includes therapies targeting conditions such as infantile GM1 gangliosidosis, frontotemporal dementia caused by progranulin deficiency, infantile Krabbe disease, metachromatic leukodystrophy, and amyotrophic lateral sclerosis. Passage Bio collaborates with leading research institutions to advance its portfolio of innovative treatments. The company was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.
Address
One Commerce Square, 39th Floor 2005 Market Street
Philadelphia, 19103
United States
Year founded
2017
Number of employees
0-100
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
